Treatment of chronic @entity110 in children with antihistamines and XXXX .

@entity1 @entity16206 @entity566 @entity14687 @entity205 @entity110
BACKGROUND: @entity14687 , daily hives that last >6 weeks, can be resistant to antihistamines, even when higher than conventional doses are used. Other pharmacologic agents have been associated with inconsistent benefit. OBJECTIVE: We examined the relationship of clinical characteristics and the presence of autoimmune antibodies to @entity16206 resistance in @entity1 . We further examined the efficacy and safety of @entity205 in @entity1 whose @entity110 was resistant to @entity16206 . METHODS: @entity1 referred to the pediatric @entity566 and pulmonary specialty clinic at the University of Iowa @entity1 's Hospital and diagnosed as having chronic idiopathic @entity110 were identified during the period from August 2008 to July 2013. A retrospective examination of treatment and outcome was performed. RESULTS: Forty-six @entity1 , 26 female @entity1 and 20 male @entity1 , with chronic idiopathic @entity110 were identified. The ages of 16 @entity1 who were @entity16206 resistant ranged from 9 to 18 years (median, 12.5 years). Those @entity1 who were @entity16206 responsive had a median age of 6 years, significantly lower than those who were @entity16206 resistant (P  = .0001). There was no significant association between autoimmune antibodies and @entity16206 resistance. All the @entity1 who were @entity16206 resistant were treated with @entity205 ; all experienced complete resolution of @entity110 at times that ranged from 2 days to 3 months (median, 7 days). Relapses responsive to repeated @entity205 occurred in 5 of the @entity1 after 1 week to 15 months (median, 6 months). Adverse effects were not seen in these @entity1 . CONCLUSION: Our data were consistent with efficacy and safety of @entity205 for chronic @entity110 in @entity1 when even high doses of antihistamines are ineffective.
